Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2A Safety and Biomarker Study of EPI-589 in Mitochondrial Subtype and Idiopathic Parkinson's Disease Subjects

NCT02462603 is registered in ClinicalTrials.gov with Edison Pharmaceuticals Inc as lead sponsor.

NCT NCT02462603
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02462603 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2A Safety and Biomarker Study of EPI-589 in Mitochondrial Subtype and Idiopathic Parkinson's Disease Subjects
Lead sponsor
Edison Pharmaceuticals Inc
Phase
Phase 2
Overall status
Completed
Start date
May 17, 2016
Completion date
January 8, 2019
Enrollment
44 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

parkinson's disease